CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Dex Liquidating Co. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Dex Liquidating Co.
900 Saginaw Drive
Phone: (650) 364-9975p:650 364-9975 Redwood City, CA  94063-4753  United States Fax: (650) 369-4024f:650 369-4024

This company's Plan of Liquidation went into effect on 11/28/2018
This company ceased filing statements with the SEC on 11/28/2018.
This entity represents the bankrupt estate of the former business (assets) of Dextera Surgical Inc. that was not sold to Aesculap, Inc., a subsidiary of B Braun Melsungen AG, on 2/20/2018.
This company is no longer actively traded on any major stock exchange.

Business Summary
Dex Liquidating Co., formerly Dextera Surgical Inc., designs and manufactures stapling devices that enable the advancement of minimally invasive surgical procedures. The Company is engaged in commercializing and developing its MicroCutter 5/80 stapler based on its staple-on-a-strip technology for use by thoracic, pediatric, bariatric, colorectal and general surgeons. Its MicroCutter 5/80 is a commercially available cartridge-based microcutter device with approximately five millimeter shaft diameter, over 80 degrees of articulation, and an approximately 30 millimeter staple line cleared for specified indications for use in the United States, and in the European Union (EU) for a range of indications for use. It manufactures and markets automated anastomotic systems used by surgeons to perform anastomoses during on- or off-pump coronary artery bypass graft procedures and these products include the C-Port xA system, the C-Port Flex A system and the PAS-Port Proximal Anastomosis System.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/20176/30/2017YesYesYes-Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Principal Executive Officer, Chief Financial Officer, Vice President - Finance Robert Y.Newell 68 3/1/2018 3/1/2003
Chief Restructuring Officer MatthewEnglish
Director Michael A.Bates 57 12/11/2015 12/11/2015
Director JulianNikolchev 62 3/1/2018 10/15/2015

Business Names
Business Name
CARDICA INC
Cardica Inc.
Cardica, Inc.
CRDC
DXTR
DXTRQ

General Information
Number of Employees: 50 (As of 6/30/2017)
Outstanding Shares: 48,206,226 (As of 10/3/2017)
Shareholders: 47
Stock Exchange: OTC
Federal Tax Id: 943287832
Fax Number: (650) 369-4024


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023